VK2735's manufacturing alliance with CordenPharma
Viking secures a manufacturing alliance with CordenPharma, promising "metric tons" of production of VK2735
We've briefly covered Viking Therapeutic's VK2735 in the past:
Viking Therapeutic’s new GLP1 produces oustanding results
At ObesityWeek 2024, Viking Therapeutic showed study results on their new drug VK2735 -- 8% body weight loss at 28 days, in the highest dose.
GLP1.Guide Staff
It's produced great results in the past, and recently some more exciting announcements have been made: Viking is partnering with CordenPharma to ensure manufacturing capability for their VK2735 GLP1-agonist.
According to the press release, "multiple metric tons" of VK2735:
Under the terms of the agreement, Viking has secured dedicated capacity for the manufacture of, and a commitment to supply annually, multiple metric tons of VK2735 API.
In addition, CordenPharma will provide fill/finish capacity for both the injectable and oral formulations of VK2735.
This includes dedicated manufacturing lines and an annual commitment to supply 100 million autoinjectors and an additional 100 million vial and syringe products for the subcutaneous formulation, as well as an annual capacity of over one billion oral VK2735 tablets. These API and final finished product capacities are further expandable at Viking's option.
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735
Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector…
Want to read more about Viking Therapeutics and CordenPharama, along with VK2735? The rest of this article is no longer available for free – if you'd like to read the rest of our analysis, check us out on Substack:
